Library / Peptides / Immune Support / Thymosin Alpha-1

Strong evidence · Grade A

Thymosin Alpha-1

Thymosin Alpha-1 (Zadaxin)

Score

85 / 100

Class

Immune Support

Brand

Zadaxin

Status

Strong Evidence

TL;DR

Thymosin Alpha-1 is a well-studied immune-regulating peptide that has been approved in dozens of countries for viral hepatitis treatment. Unlike simple immune boosters, it intelligently calibrates immune response — ramping up defenses against viruses and cancer while helping to control runaway inflammation. It has an excellent safety record and solid clinical trial data, though it is not yet FDA-approved in the US.

Part 01 · How it works

Mechanism.

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5 of bovine thymus by Allan Goldstein in the 1970s. The synthetic version (Zadaxin/thymalfasin) is approved in over 35 countries for treatment of hepatitis B, hepatitis C, and as a vaccine adjuvant, and has been studied extensively in cancer, sepsis, and COVID-19. It is one of the most clinically validated immunomodulatory peptides available.

Thymosin Alpha-1 is like a commander who can read the battlefield and direct the immune army appropriately — turning up attack forces when there is a virus or tumor, and calling for de-escalation when inflammation is getting out of hand. It brings intelligent coordination rather than simply boosting immune activity.

Mechanism · technical

Thymosin Alpha-1 acts on toll-like receptors (particularly TLR2/TLR9) and dendritic cells to promote Th1 immune polarization, enhance NK cell activity, increase IL-2 and interferon-gamma production, and improve T-cell maturation. It upregulates MHC class I expression on tumor and virally infected cells, enhancing cytotoxic T-lymphocyte (CTL) recognition and killing. It also modulates regulatory T-cell function and can suppress excessive inflammatory responses in sepsis.

Part 02 · Dosing & administration

How it's taken.

Values below describe how Thymosin Alpha-1 has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose

1.6 mg

Subcutaneous injection · Twice weekly

Duration

6-12 months for hepatitis B; shorter courses for immune support

Approved in many countries as Zadaxin for hepatitis B and as immune adjuvant. Not FDA-approved in USA. Well-studied safety profile with >30 countries' approval. Stimulates dendritic cells and T-cell maturation.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator

Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects

Exceptionally well-tolerated across thousands of patients in clinical trials. Mild injection site reactions. Rare flu-like symptoms. No significant organ toxicity identified. Long safety record from over 35 years of clinical use in approved markets.

Absolute · do not use

Pregnancy or breastfeeding

Children under 18 (unless under specialist care)

Known hypersensitivity to thymosin alpha-1 or any component

Organ transplant recipients on immunosuppression (risk of graft rejection)

Active autoimmune disease in flare (may exacerbate autoimmunity)

Interactions

Immunosuppressants (tacrolimus, cyclosporine)

Thymosin alpha-1 stimulates T-cell and dendritic cell function; directly opposes immunosuppressive therapy

Major

Immune checkpoint inhibitors

Additive immune activation; increased risk of immune-related adverse events

Moderate

Interferon-alpha

Often used in combination for hepatitis B/C; additive immune activation with potential for enhanced efficacy but also increased side effects

Moderate

Corticosteroids

High-dose corticosteroids may reduce thymosin alpha-1 efficacy by suppressing immune function

Moderate

Labs to monitor

CBC with Differential

Baseline and monthly

Monitor immune cell counts and T-cell response

T-Cell Subsets (CD4, CD8)

Baseline and at end of treatment

Primary mechanism is T-cell activation

CMP (Comprehensive Metabolic Panel)

Baseline and every 3 months

Liver function (used in hepatitis B treatment)

Hepatitis B Viral Load

Per hepatology protocol

If used for HBV (approved indication in some countries)

CRP / ESR

Baseline and monthly

Track inflammatory/immune markers

Part 04 · Evidence

How strong is the evidence?

Scores derived from rating, indexed studies, regulatory status, and catalogued safety data for this peptide. Curated per-peptide scoring replaces this when available.

Grade A

Grade A. Evidence is strongest where indications match regulatory approval — pair with a clinician when applying beyond label.

Clinical efficacy

Rating reflects consistent peer-reviewed evidence in its indication.

Study quality

4 indexed studies in our dataset. Designs vary — see Research log for per-study grades.

Regulatory clarity

FDA-approved for at least one indication.

Safety profile

Based on 5 documented contraindications, 4 interactions, 5 lab checkpoints.

Long-term data

Years of post-approval surveillance available.

Part 05 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

2013

Thymalfasin (Thymosin Alpha-1) for hepatitis B: meta-analysis of randomized trials

Meta-analysis of 15 RCTs (n=1,101 patients) showed Tα1 significantly improved HBeAg seroconversion, HBV-DNA loss, and ALT normalization in chronic hepatitis B versus controls.

Predominance of Asian trials; heterogeneity in outcome measures; some trials included combination with interferon.

PMID 23558285 ↗

2019

Thymosin Alpha-1 in sepsis: the SMILE trial

The SMILE RCT in septic patients showed Tα1 significantly improved 28-day survival and reduced secondary infections compared to placebo, with no increase in adverse events.

Single-country RCT (China), sample size moderate (n=361). Requires multi-center replication in Western populations.

PMID 31359045 ↗

2020

Thymosin Alpha-1 as adjunctive treatment in severe COVID-19

Observational and preliminary RCT data from China showed Tα1 treatment in severe COVID-19 patients was associated with reduced mortality, faster lymphocyte recovery, and lower inflammatory markers.

Early pandemic data, varying study quality, mostly Chinese centers. Publication bias likely. Findings are promising but require replication.

PMID 32822468 ↗

2016

Immune modulation by Thymosin Alpha-1 in cancer: a systematic review

Tα1 as adjunct to chemotherapy or radiation was associated with improved response rates and quality of life in hepatocellular carcinoma and lung cancer in multiple RCTs.

Heterogeneous cancer types and treatment regimens. Most trials conducted in Asia. Survival data inconsistent across studies.

PMID 27558856 ↗

Part 06 · Cost & access

Where you can get it.

Regulatory status

Approved in 35+ countries (including China, Italy, Philippines, Mexico) as Zadaxin for hepatitis B, hepatitis C, and as immunostimulant. Not FDA-approved in the US — classified as investigational. Available in US as research peptide; compounding pharmacies may prepare it for off-label use under physician supervision.

The Peptide Column takes no affiliate commission from any source.

Part 07 · Your appointment

Questions to bring.

Is Thymosin Alpha-1 available through legitimate pharmaceutical channels (Zadaxin) versus research peptide suppliers?

Given my specific condition, does the evidence support Thymosin Alpha-1 use and what dosing protocol is appropriate?

Are there any interactions with immunosuppressive medications I may be taking?

What monitoring is recommended to assess immune response during treatment?